Legend Biotech Corporation vs Merck & Company, Inc. — Stock Comparison
Legend Biotech Corporation (LEGN) and Merck & Company, Inc. (MRK) are both listed on US exchanges. This page compares their Q·Score ratings, key fundamentals (P/E, margins, growth), and Wall Street analyst consensus side by side. Data sourced from Yahoo Finance and updated on each page load.
Merck & Company, Inc. scores ahead of Legend Biotech Corporation on Q·Score (7 vs 6.2 out of 10), led by Quality (7.7 vs 0.9) and Growth (6.2 vs 5.8). Legend Biotech Corporation scores higher on Valuation, reflecting stronger P/E and price-target positioning. Analyst consensus targets imply greater upside for LEGN (+106.2%) than for MRK (+13.9%).
Price Performance
Normalised to 100 at period start — shows relative performance.
Q·Score Breakdown
Consensus analyst target of $57.59 is 106% above current price.
⚠ currently unprofitable (-22% margin).
High-quality business with 19% return on equity and 14% profit margins.
Analyst Consensus
Fundamentals
Frequently Asked Questions
LEGN vs MRK: which stock scores better overall?
Based on Q·Score, Merck & Company, Inc. (MRK) scores 7/10 versus Legend Biotech Corporation (LEGN) at 6.2/10. The Q·Score measures five dimensions: Quality, Health, Growth, Valuation, and Sentiment. For informational purposes only — not financial advice.
Which has better revenue growth: LEGN or MRK?
Merck & Company, Inc. (MRK) scores higher on Growth (6.2/10 vs 5.8/10). Legend Biotech Corporation reports revenue growth (56.5% YoY) while Merck & Company, Inc. reports (4.9% YoY). Growth scores reflect revenue and earnings momentum relative to sector peers.
Is LEGN or MRK more attractively valued?
Legend Biotech Corporation (LEGN) scores higher on Valuation (9.6/10 vs 6.7/10). LEGN trades at 20.9× P/E versus MRK at 11.9×. Valuation is assessed using P/E ratio, analyst price targets, and 52-week range positioning relative to sector peers.
What do analysts say about LEGN vs MRK?
There are 15 analysts covering LEGN with a consensus price target of $57.59, and 27 analysts covering MRK with a consensus target of $129.74. Analyst consensus ratings are aggregated from Wall Street research and do not constitute investment advice.
Which is more profitable: LEGN or MRK?
Merck & Company, Inc. (MRK) scores higher on Quality (7.7/10 vs 0.9/10). Net profit margin: LEGN at -22.0%, MRK at 13.6%. Quality scores reflect profit margins, return on equity, and free cash flow generation.
Which has stronger financial health: LEGN or MRK?
Legend Biotech Corporation (LEGN) scores higher on Financial Health (8.1/10 vs 7/10). Market beta: LEGN at 0.35, MRK at 0.22. Health scores consider beta, debt-to-equity, and current ratio. All investments carry risk — this is not investment advice.
What are the market caps of LEGN and MRK?
Legend Biotech Corporation (LEGN) has a market capitalisation of $5.2B, while Merck & Company, Inc. (MRK) has a market cap of $281.2B. Market cap data is sourced from Yahoo Finance and reflects the most recent available figures.
Do LEGN or MRK pay dividends?
LEGN does not currently pay a dividend, while MRK pays a dividend yield of 2.95%. Dividend yields fluctuate with share price and company payout decisions.
Related Comparisons
Q·Score is an educational tool and is not financial advice. Data provided by Yahoo Finance. Updated on each page load. How it's calculated →